Vrancken Kristof, Paeshuyse Jan, Liekens Sandra
Rega Institute for Medical Research, KU Leuven, Leuven, Belgium.
Antivir Chem Chemother. 2012 Jan 17;22(4):159-70. doi: 10.3851/IMP1987.
Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. The limited treatment options and poor prognosis of HCC patients underscore the importance of developing new therapeutic strategies. Infection with HBV and HCV are the major risk factors for developing HCC. While the precise molecular mechanisms that link HBV and HCV infections to the development and progression of HCC are not entirely understood, increasing evidence indicates that stimulation of angiogenesis by these viruses may contribute to HCC malignancy. In this review, we summarize the progress in understanding the role of HBV and HCV infection in liver and HCC angiogenesis, the mechanisms applied by these viruses to deregulate the angiogenic balance and the potential therapeutic options that come with this understanding.
肝细胞癌（HCC）是全球最常见的癌症之一。HCC患者的治疗选择有限且预后较差，这凸显了开发新治疗策略的重要性。感染乙肝病毒（HBV）和丙肝病毒（HCV）是发生HCC的主要危险因素。虽然将HBV和HCV感染与HCC发生及进展联系起来的确切分子机制尚未完全明确，但越来越多的证据表明，这些病毒对血管生成的刺激可能促使HCC发生恶变。在本综述中，我们总结了在理解HBV和HCV感染在肝脏及HCC血管生成中的作用、这些病毒破坏血管生成平衡所采用的机制以及基于这一认识的潜在治疗选择方面取得的进展。
